Vernalis Research

We have generated six development candidates in the past six years and cell active lead compounds against 15 different targets. Our successes include projects in close collaboration with companies such as Lundbeck, Novartis, Servier, Genentech, Asahi Kasei Pharma and Taisho. Our strengths are in developing and applying the most appropriate structure-based methods to work with our partners to solve problems in drug discovery.

 

For more information please visit www.vernalis-research.com

 

Latest News

Unaudited Interim Results for the six months ended 31 December 2016

Vernalis plc (LSE: VER) today announces its unaudited consolidated results for the six month period ended 31 December 2016. 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch